• Welcome to Baptist Board, a friendly forum to discuss the Baptist Faith in a friendly surrounding.

    Your voice is missing! You will need to register to get access to all the features that our community has to offer.

    We hope to see you as a part of our community soon and God Bless!

Pfizer vaccine's protection against Omicron drops as soon as three weeks after third dose: Study

Revmitchell

Well-Known Member
Site Supporter
The effectiveness of Pfizer and BioNTech's COVID-19 vaccine wanes rapidly against the Omicron variant, beginning to fade away as soon as three weeks after the second or third dose, a new study finds.

Researchers said that the antibody responses induced by a second and third dose of the vaccine were "transient" and that "additional booster doses may be necessary," although the vaccine still provides enough immunity to ward off hospitalization and death from COVID-19.

The Danish study, which was published in JAMA Network Open on Friday, examined 128 people who had received two or three doses of Pfizer/BioNTech's mRNA vaccine.

Pfizer vaccine's protection against Omicron drops as soon as three weeks after third dose: Study
 

Wingman68

Well-Known Member
Site Supporter
Is anyone surprised?

STORY AT-A-GLANCE
  • In November 2021, Brook Jackson, a whistleblower who worked on Pfizer’s Phase 3 COVID jab trial in the fall of 2020, warned she’d seen evidence of fraud in the trial
  • With the release of Pfizer trial data — which they tried to withhold for 75 years — additional problems suggestive of fraud and data manipulation are coming to light
  • Trial site 1231, located in Argentina, somehow managed to recruit 10% of the total trial participants, 4,501 in all, and they did so in just three weeks, and without a contract research organization — a feat that has many questioning whether fraud was committed
  • The lead investigator for trial site 1231 is Dr. Fernando Polack, who also happens to be a consultant for the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (RBPAC), a current adjunct professor at Vanderbilt University in Tennessee, an investigator for Fundación Infant, funded by the Bill & Melinda Gates foundation, and the first author of Pfizer’s paper, “Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,” published at the end of December 2021
  • Site 1231 held a second enrollment session, given the designation of “site 4444.” The 4444 trial site data raise another red flag. It supposedly enrolled 1,275 patients in a single week, from September 22 through 27, 2020 — the last week that recruitment could take place to meet the data cutoff for the FDA meeting in December 2020. Was “site 4444” fabricating data to create the appearance that the jab was having an effect?
Whistleblower Accuses Pfizer of Fraud in Its COVID Vaccine Research
 
Top